CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors – Nature

Nature, Published online: 09 October 2024; doi:10.1038/s41586-024-07943-7

Alterations in the tumour suppressor genes STK11 and/or KEAP1 can identify patients with advanced non-small-cell lung cancer who are likely to benefit from combinations of PD-(L)1 and CTLA4 immune checkpoint inhibitors added to chemotherapy.